Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors
Treatment adherence is crucial for optimal outcomes in advanced breast cancer, but can be challenging due to various factors, i.e. patients’ attitudes and behavior upon diagnosis, and complex therapies with high adverse effect rates. Our aim was to explore the adherence to oral anticancer medication...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2023-12-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2023-0045 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568669420388352 |
|---|---|
| author | Baković Matea Bago Martina Benić Lucija Krajinović Magdalena Silovski Tajana Plavetić Natalija Dedić Turković Lu Sertić Miranda Hadžiabdić Maja Ortner |
| author_facet | Baković Matea Bago Martina Benić Lucija Krajinović Magdalena Silovski Tajana Plavetić Natalija Dedić Turković Lu Sertić Miranda Hadžiabdić Maja Ortner |
| author_sort | Baković Matea |
| collection | DOAJ |
| description | Treatment adherence is crucial for optimal outcomes in advanced breast cancer, but can be challenging due to various factors, i.e. patients’ attitudes and behavior upon diagnosis, and complex therapies with high adverse effect rates. Our aim was to explore the adherence to oral anticancer medications (OAM) in women with advanced breast cancer, focusing on cyclin-dependent kinase 4 and 6 inhibitors (CDKI), and identify factors associated with the adherence. We conducted a cross-sectional study at the University Hospital Centre Zagreb, Croatia, involving women with stage IV advanced breast cancer receiving OAM. Data collection included a questionnaire assessing socio-demographic and clinical information, Beck Depression Inventory-II for depressive symptoms, Medication Adherence Report Scale (MARS-5) for adherence to OAM, and Beliefs about Medicines Questionnaire. Plasma concentrations of CDKI were confirmed by LC-MS/MS in three randomly selected participants. A total of 89 women were included. The most prescribed OAMs were anti-estrogen (71.3 %) and CDKI (60.9 %). MARS-5 scores (mean: 24.1 ± 1.6) correlated with CDKI plasma concentrations. Forgetfulness was the primary reason for non-adherence (25.9 %). Women receiving CDKI (p = 0.018), without depressive symptomatology (p = 0.043), and with more positive beliefs about medicines were more adherent (p < 0.05). This study enhances understanding of medication adherence in advanced breast cancer and identifies influential factors. |
| format | Article |
| id | doaj-art-d0e30c0346e9458f8a1cd257fb165870 |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-d0e30c0346e9458f8a1cd257fb1658702025-02-03T00:57:31ZengSciendoActa Pharmaceutica1846-95582023-12-0173463365410.2478/acph-2023-0045Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitorsBaković Matea0Bago Martina1Benić Lucija2Krajinović Magdalena3Silovski Tajana4Plavetić Natalija Dedić5Turković Lu6Sertić Miranda7Hadžiabdić Maja Ortner81University of Zagreb, Faculty of Pharmacy and Biochemistry, 10000Zagreb, Croatia2Andrija Štampar Teaching Institute of Public Health10000Zagreb, Croatia1University of Zagreb, Faculty of Pharmacy and Biochemistry, 10000Zagreb, Croatia1University of Zagreb, Faculty of Pharmacy and Biochemistry, 10000Zagreb, Croatia3University Hospital Centre, Department of Oncology10000Zagreb, Croatia3University Hospital Centre, Department of Oncology10000Zagreb, Croatia1University of Zagreb, Faculty of Pharmacy and Biochemistry, 10000Zagreb, Croatia1University of Zagreb, Faculty of Pharmacy and Biochemistry, 10000Zagreb, Croatia1University of Zagreb, Faculty of Pharmacy and Biochemistry, 10000Zagreb, CroatiaTreatment adherence is crucial for optimal outcomes in advanced breast cancer, but can be challenging due to various factors, i.e. patients’ attitudes and behavior upon diagnosis, and complex therapies with high adverse effect rates. Our aim was to explore the adherence to oral anticancer medications (OAM) in women with advanced breast cancer, focusing on cyclin-dependent kinase 4 and 6 inhibitors (CDKI), and identify factors associated with the adherence. We conducted a cross-sectional study at the University Hospital Centre Zagreb, Croatia, involving women with stage IV advanced breast cancer receiving OAM. Data collection included a questionnaire assessing socio-demographic and clinical information, Beck Depression Inventory-II for depressive symptoms, Medication Adherence Report Scale (MARS-5) for adherence to OAM, and Beliefs about Medicines Questionnaire. Plasma concentrations of CDKI were confirmed by LC-MS/MS in three randomly selected participants. A total of 89 women were included. The most prescribed OAMs were anti-estrogen (71.3 %) and CDKI (60.9 %). MARS-5 scores (mean: 24.1 ± 1.6) correlated with CDKI plasma concentrations. Forgetfulness was the primary reason for non-adherence (25.9 %). Women receiving CDKI (p = 0.018), without depressive symptomatology (p = 0.043), and with more positive beliefs about medicines were more adherent (p < 0.05). This study enhances understanding of medication adherence in advanced breast cancer and identifies influential factors.https://doi.org/10.2478/acph-2023-0045advanced breast canceroral anticancer therapycdk 4/6 inhibitorsadherencedepressive symptomsbeliefs about medicines |
| spellingShingle | Baković Matea Bago Martina Benić Lucija Krajinović Magdalena Silovski Tajana Plavetić Natalija Dedić Turković Lu Sertić Miranda Hadžiabdić Maja Ortner Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors Acta Pharmaceutica advanced breast cancer oral anticancer therapy cdk 4/6 inhibitors adherence depressive symptoms beliefs about medicines |
| title | Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors |
| title_full | Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors |
| title_fullStr | Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors |
| title_full_unstemmed | Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors |
| title_short | Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors |
| title_sort | exploring adherence in patients with advanced breast cancer focus on cdk4 6 inhibitors |
| topic | advanced breast cancer oral anticancer therapy cdk 4/6 inhibitors adherence depressive symptoms beliefs about medicines |
| url | https://doi.org/10.2478/acph-2023-0045 |
| work_keys_str_mv | AT bakovicmatea exploringadherenceinpatientswithadvancedbreastcancerfocusoncdk46inhibitors AT bagomartina exploringadherenceinpatientswithadvancedbreastcancerfocusoncdk46inhibitors AT beniclucija exploringadherenceinpatientswithadvancedbreastcancerfocusoncdk46inhibitors AT krajinovicmagdalena exploringadherenceinpatientswithadvancedbreastcancerfocusoncdk46inhibitors AT silovskitajana exploringadherenceinpatientswithadvancedbreastcancerfocusoncdk46inhibitors AT plaveticnatalijadedic exploringadherenceinpatientswithadvancedbreastcancerfocusoncdk46inhibitors AT turkoviclu exploringadherenceinpatientswithadvancedbreastcancerfocusoncdk46inhibitors AT serticmiranda exploringadherenceinpatientswithadvancedbreastcancerfocusoncdk46inhibitors AT hadziabdicmajaortner exploringadherenceinpatientswithadvancedbreastcancerfocusoncdk46inhibitors |